Wellstone

News and Events

7/30/2012 Wellstone Center scientists discover alternative disease mechanism for FSHD that establishes that DUX4 expression per se is not sufficient for FSHD muscle pathology and indicate that FSHD is controlled by family-specific genetic modifiers that modulate DUX4 expression and function
Arrow

11/23/2011 Wellstone MD CRC publishes paper in European Journal of Human Genetics that finds significant differences among cells from different family cohorts, and these differences were independent of disease status, gender, or muscle biopsied. Thus, though none of the properties we examined could be used to reliably distinguish between FSHD and unaffected cells, family of origin was an important contributor to gene-expression patterns and stressor responses in cultures of both FSHD and unaffected myogenic cells
Arrow

11/07-08/2011 Wellstone MD CRC hosts 2011 FSHD International Research Consortium Workshop and Planning days for near 100 researchers and presents latest findings and makes more biomaterials collections available
Arrow

7/12/2011 Announcement of muscle cell distribution and availability of FSHD and control primary skeletal muscle cell strains and immortalized clonal cell lines
Arrow

5/3/2009 March of Dimes Awards $250,000 Prize to Louis Kunkel [co-Director BBRI Wellstone MD CRC FSHD] for Significant Contributions to Understanding the Causes of Muscular Dystrophy
Arrow

Featured

FauxThumbnail Johns Hopkins School of Medicine and Kennedy Krieger Institute Recruiting Volunteers with FSHD for Clinical Research Arrow

FauxThumbnailFSHD Patients and unaffected family members please contact the Wellstone MD CRC Office of Patient Communication and Liaison for assistance in enrolling in research studiesArrow

FauxThumbnailInvestigators are requested to contact us to tap national FSHD biomaterials resources and to establish collaborationsArrow

FauxThumbnailFirst Muscle Biopsies Arrive at the NIH BBRI Senator Paul Wellstone FSHD Center in Massachusetts!Arrow

FauxThumbnailLearn About Faccioscapulohumeral Muscular Dystrophy (FSHD) — the Most Prevalent Muscular Dystrophy, and How it Impacts Individuals, Families and Patients Arrow

FauxThumbnailLearn About Physical Therapy, Exercise and FSHDArrow

The NIH-supported Boston Biomedical Research Institute Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center for FSHD will further the understanding of the underlying molecular and cellular pathology of facioscapulohumeral muscular dystrophy (FSHD) and is establishing muscle tissue and cell repository biomarker databases as resources for FSHD research and evaluation of outcomes of FSHD clinical trials. The Center is led by Dr. Charles P. Emerson at the Boston Biomedical Research Institute, and Dr. Louis Kunkel at Children’s Hospital Boston and Harvard Medical School, and includes investigators at Kennedy Krieger Institute, Johns Hopkins Hospital, Boston Biomedical Research Institute, University of Sao Paolo, University of Maryland School of Medicine, and the University of Texas Southwestern Medical Center. The Center partners with the FSH Society for patient outreach activities and with two biotechnology companies, Acceleron Pharma and Genzyme/Myosix, for therapeutic development.